Rheumatoid arthritis and cardiovascular pathology

Ревматоидты артрит және жүрек қан тамыр патологиясы
Saule Abisheva 1, Nurlan Batpenov 2, Zhadra Amangeldiyeva 1, Kanagat Abdiramasheva 3
More Detail
1 Department of Internship General Practice, Astana Medical University, Astana, Republic of Kazakhstan
2 Arthrology Department, Scientific and Research Institute of Traumatology and Orthopedics, Astana, Republic of Kazakhstan
3 Department of Propaedeutics and Internal Diseases, Akhmed Yassawi International Kazakh-Turkish University, Turkestan, Republic of Kazakhstan
J CLIN MED KAZ, Volume 1, Issue 47, pp. 8-13. https://doi.org/10.23950/1812-2892-JCMK-00541
OPEN ACCESS 3238 Views 2410 Downloads
Download Full Text (PDF)

ABSTRACT

The article discusses the problematic issues of cardiovascular pathology in rheumatoid arthritis. The latest data on the influence of traditional risk factors for cardiovascular pathology, autoimmune chronic inflammation, antirheumatic drugs on the development of cardiovascular complications are provided.
Keywords: rheumatoid arthritis, cardiovascular pathology, traditional risk factors, autoimmune inflammation

CITATION

Abisheva S, Batpenov N, Amangeldiyeva Z, Abdiramasheva K. Rheumatoid arthritis and cardiovascular pathology. Journal of Clinical Medicine of Kazakhstan. 2018;1(47):8-13. https://doi.org/10.23950/1812-2892-JCMK-00541

REFERENCES

  • Nasonov E.L. Revmatologija: nacional’noe rucovodstvo (Reumatology: National guide) [in Russian]. Moscow: Geotar-Media; 2008. 720 p.
  • Mazurov V.I. Klinicheskaja revmatologija: rukovodstvo dlja prakticheskih vrachej (Clinical rheumatology: a guide for practitioners) [in Russian]. Saint-Peterburg: Foliant; 2011. 520 p.
  • Togizbaev G.A., Shamitekov I.M., Bermagambetova G.N. Rasprostranennost’ i social’naja znachimost’ revmatoidnogo artrita v Respublike Kazahstan (Prevalence and social significance of rheumatoid arthritis in the Republic of Kazakhstan) [in Russian]. Materialy I Evrazijskogo kongressa revmatologov. Almaty; 2012, pp.102-104.
  • Parodi M. et al. Comorbidities in rheumatoid arthritis: analysis of hospital discharge records. Reumatismo. 2005;57:154-160.
  • Global status report on noncommunicable diseases. Geneva: World Health Organization; 2010. 162 p.
  • Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization; 2013. 163 p.
  • Berkinbaev S.F., Dzhunusbekova G.A., et al. Rasprostranennost’ faktorov riska osnovnyh SSZ sredi zhitelej JuKO (Prevalence of risk factors for major cardiovascular diseases among residents of the South Kazakhstan region) [in Russian]. Vestnik KAZNMU. 2011; 2:76-80.
  • Kitas G.D., Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford). 2003;42:607–613.
  • Kaplan M.J. Is rheumatoid arthritis a risk factor for cardiovascular disease? Nature Clinical Practice Rheumatology. 2007;3:260– 261.
  • Nurmohamed M. T., et al. Rheumatic diseases as risk factors for cardiovascular disease. Nederlands Tijdschrift Voor Geneeskunde. 2006;150:1921–1924.
  • Gonzalez A., et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann. of the Rheumatic Diseases. 2008;67:64–69.
  • Gabriel S. E. Heart disease and rheumatoid arthritis: understanding the risks. Ann. of the Rheumatic Diseases. 2010; 69:61–64.
  • Peters M. J., et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis & Rheumatism. 2009;61:1571–1579.
  • Van Halm V. P., et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann. of the Rheumatic Diseases. 2009;68:1395–1400.
  • Popkova T.V., Novikova D.S., Nasonov E.L. Ateroskleroz pri revmaticheskih zabolevanijah. V kn.: Revmatologija: klinicheskie rekomendacii (Atherosclerosis in rheumatic diseases. In: Reumatology: clinical guidelines) Moscow: Geotar-Media; 2010. p. 678–702.
  • Peters M.J., Symmons D.P., McCarey D.W., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis – TASK FORCE «Cardiovascular risk management in RA». Ann Rheum Dis. 2010;69(2):325–31.
  • Meune C., Touze E., Trinqurte L. et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology. 2009;48(10):1309–13. 
  • Gorbunova Ju.N, Novikova D.S, Popkova T.V i dr. Kardiovaskuljarnyj risk u bol’nyh rannim revmatoidnym artritom do naznachenija bazisnoj protivovospalitel’noj terapii (predvaritel’nye dannye issledovanija REMARKA) (Cardiovascular risk in patients with early rheumatoid arthritis before disease-modifying antirheumatic therapy (preliminary data of the REMARCА study) [in Russian]. Nauchno-prakticheskaja revmatologija. 2014;52(4):381-386.
  • Baghdadi L.R., Woodman R.J., Shanahan E.M., Mangoni A.A. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One. 2015;10(2):1- 18.
  • Nasonov E.L. Problema aterotromboza v revmatologii (The problem of atherothrombosis in rheumatology) [in Russian]. Vestnik RAMN. 2003;7:6-10.
  • Teir J, Koduri G, Meadows A., et al. Letter to the editor (other). An audit of recording cardiovascular risk factors in patients with rheumatoid arthritis and systemic lupus erythematosus in centres in East Anglia and the South East. Rheumatology, 2008;1-3.
  • Giles J, Post W, Blumenthal R. et al. Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nature lin. Pract. Rheumatology. 2006;2,6:320-329.
  • Popkova T.V., Novikova D.S., Nasonov E.L. Serdechno-sosudistye patologii pri revmatoidnom artrite: novye dannye (Cardiovascular diseases in rheumatoid arthritis: latest data) [in Russian]. Nauchno-prakticheskaja revmatologija. 2016;54(2):122- 128.
  • Mazurov V.I., Stolov C.B., Jakusheva V.A., et al. Kardiovaskuljarnye problemy v revmatologii (Cardiovascular problems in rheumatology) [in Russian]. Nauchno-prakticheskaja revmatologija. 2006;4:28-34.
  • Barbarroja N., Perez-Sancherz C., Ouiz-Limon P., et al. Anti-cyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Arterioscler Thromb Vasc Biol. 2014;34:2706-2716.
  • Del Rincon I.D., Williams K., Stern M.P., et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737–2745.
  • Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis Circulation. 2002;105:1135–1143.
  • Liuzzo G., Colussi C., Ginnetti F., et al. C-reactive protein directly induces the activation of the transcription factor NFкВin human monocytes: a clue to pathogenesis of acute coronary syndromes? Eur.Heart J. 2001;22:372.
  • Nasonov. E. L. Immunologicheskie markery ateroskleroza. Antifosfolipidnyj sindrom (Immunological markers of atherosclerosis. Antiphospholipid syndrome) [in Russian]. Moscow: Littera; 2004. 278 –298p.
  • Abou-Raya A., Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev. 2006;5(5):331 – 337.
  • Chung C.P., Avalos I., Raggi P., Stein, C.M. Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin. Rheumatol. 2007;26(8):1228 –1233.
  • Montecucco F., Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford). 2009;48:11–22.
  • Sattar N., Mclnnes I.B. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol. 2005;17:286–292.
  • Tedgui A., Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res. 2001;11:877–87.
  • Brennan F.M., McInnes I.B. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118:3537–3545.
  • Sarwar A.B, Sarwar A., Rosen B.D., Nasir K. Measuring subclinical atherosclerosis: is homocysteine relevant? Clin Chem Lab Med. 2007;45(12):1667–1677.
  • Hurlimann D., Enseleit F., Ruschitzka F. Rheumatoid arthritis, inflammation and atherosclerosis. Rheumatol. 2004;29(8):760 – 768.
  • Dessein P.H, Joffe B.I., Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther. 2005;7(3):634 – 643.
  • Dessein P.H., Norton G.R., Woodiwiss A.J. et al. Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. Rheumatol. 2007;34(5):943 – 991.
  • Maradit-Kremers H., Nicola P.J., Crowson C.S., et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722-732.
  • Novikova D.S., Popkova T.V., Gerasimov A.N. i dr. Bezbolevaja ishemija miokarda i narushenija ritma serdca u zhenshhin s revmatoidnym artritom (Silent myocardial ischemia and cardiac arrhythmias in women with rheumatoid arthritis) [in Russian]. Klinicist. 2013;3-4:31-40.
  • Novikova D.S., Popkova T.V., Mach Je.S., Nasonov E.L. Opredelenie kal’cija v koronarnyh arterijah: novye vozmozhnosti stratifikacii riska razvitija serdechno-sosudistyh oslozhnenij u pacientov s autoimmunnymi zabolevanijami (Calcium evaluation in coronary arteries: new possibilities of cardiovascular complications risk stratification in patients with autoimmune diseases) [in Russian]. Nauchno-prakticheskaja revmatologija. 2009;47(3):60-66.
  • Novikova D.S., Popkova T.V., Gerasimov A.N. et al. Vzaimosvjaz’ kardiovaskuljarnyh faktorov riska s rigidnost’ju arterial’noj stenki u zhenshhin s vysokoj aktivnost’ju revmatoidnogo artrita (Calcium evaluation in coronary arteries: new possibilities of cardiovascular complications risk stratification in patients with autoimmune diseases) [in Russian]. Racional’naja farmakoterapija v kardiologii. 2012;8(6):756-765.
  • Voskuyl A.E. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology (Oxford). 2006;45 Suppl. 4:iv4-7.
  • Novikova D.S., Popkova T.V., Gerasimov A.N.i dr. Vzaimosvjaz’ velichiny intervala QT i kardiovaskuljarnyh faktorov riska u zhenshhin s revmatoidnym artritom. (The correlation between QT interval and cardiovascular risk factors in women with rheumatoid arthritis) [in Russian]. Klinicist. 2013;(1):30-6. 
  • Kirillova I.G., Novikova D.S., Popkova T.V. i dr. Diastolicheskaja disfunkcija levogo i pravogo zheludochkov u bol’nyh rannim revmatoidnym artritom do naznachenija bazisnoj protivovospalitel’noj terapii (Diastolic dysfunction of the left and right ventricles in patients with early rheumatoid arthritis before the appointment of the basic anti-inflammatory therapy) [in Russian]. Terapevticheskij arhiv. 2015;87(5):16-23.
  • Nasonov E.L. Ciklooksigenaza2 i kardiovaskuljarnaja patologija (Cyclooxygenase 2 and cardiovascular pathology) [in Russian]. Serdce. 2004;4:209–212.
  • Roubille C., Richer V., Startino T. et al. The effect of tumor necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systemic review and meta-analysis. Ann Rheunm Dis. 2015;74:480-489.
  • Boers M., Nurmohamed M.T., Doelman, CJA et al. Influence glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62:842 – 845.
  • Nasonov E.L., Mazurov V.I., Karateev D.E. i dr. Proekt rekomendacij po lecheniju revmatoidnogo artrita. Obshherossijskoj obshhestvennoj organizacii. Associacija revmatologov Rossii 2014 (Evolution of a concept. Project: recommendations on treatment of rheumatoid arthritis developed by All Russian Public organization. Association of Rheumatologists of Russia) [in Russian]. Nauchno-prakticheskaja revmatologija. 2014(chast’ 1);52(5):477-494.
  • Humphreys J.H., Warner A., Chipping J. et al. Mortality trends in patients with early rheumatoid arthritis over 20 years: Results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken). 2014;66(9):1296-1301.
  • Popkova T.V., Novikova D.S., Gasparyan A.Y., Nasonov E.L. Cardiovascular effects of methotrexate in rheumatoid arthritis. Curr Med Chem. 2015;22:1903-1910.
  • Nasonov E.L. Metotreksat:perspektivy primeneniya v revmatologii. (Methotrexate: prospects of application in rheumatology) [in Russian]. Moscow: Filomatis; 2005. 200 p.
  • Van Ede A.E., Laan R.F., Blom H.J. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2002;41(6):658–665.
  • Morgan S.L., Baggott J.E., Refsum H., Ueland P.M. Homocysteine levels in patients with rheumatoid arthritis treated with lowdose methotrexate. Clin.Pharmacol.Ther. 1991;50(5Pt1):547–556.